Pharma Pioneer

BioInvent Partners with MSD for BI-1910 and KEYTRUDA Combination Trial

17 May 2024
2 min read

BioInvent, a Swedish biotech firm specializing in innovative cancer immunotherapy antibodies, has entered into a partnership with MSD International Business GmbH, a subsidiary of Merck & Co., Inc., for a Phase 1/2a clinical trial. The trial will assess the efficacy of BioInvent's monoclonal antibody, BI-1910, when used in conjunction with Merck's KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy. MSD will supply KEYTRUDA for the study, which is set to take place across the United States and Europe and is designed to be adaptive for optimal dosage adjustments.

BI-1910 represents BioInvent's second venture into the clinical development of tumor necrosis factor receptor 2 (TNFR2) agonist antibodies, following the ongoing Phase 2a trials of BI-1808. The company's proprietary F.I.R.S.T™ technology facilitated the selection of both antibodies, which are considered potential best-in-class candidates. The solo administration phase of BI-1910's clinical trial began in December 2023, with preliminary results anticipated by the end of 2024.

Martin Welschof, CEO of BioInvent, expressed enthusiasm for the collaboration, highlighting the company's expertise in TNFR2 biology and its ongoing efforts to advance two distinct monoclonal antibodies through clinical trials. This initiative marks the fifth product in BioInvent's clinical development pipeline, underscoring the company's ability to identify novel therapeutic targets for cancer treatment.

BioInvent is a clinical-stage company listed on the Nasdaq Stockholm exchange, with a focus on discovering and developing first-in-class immuno-modulatory antibodies. The company currently has five drug candidates in Phase 1/2 trials, targeting both hematological cancers and solid tumors. Revenue is derived from research collaborations, licensing agreements with leading pharmaceutical companies, and the production of antibodies for third parties through its manufacturing division.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FibroGen Reveals Initial Findings from Phase 1 Solo Treatment Study of FG-3246 in mCRPC Patients
Pharma Pioneer
3 min read
FibroGen Reveals Initial Findings from Phase 1 Solo Treatment Study of FG-3246 in mCRPC Patients
17 May 2024
FG-3246 has shown promising results in treating adenocarcinoma within a heavily pre-treated patient group.
Read →
Promising Results from Kiromic's Deltacel-01 Trial: Safety, Tolerability, and Efficacy in Patient Three
Pharma Pioneer
3 min read
Promising Results from Kiromic's Deltacel-01 Trial: Safety, Tolerability, and Efficacy in Patient Three
17 May 2024
Kiromic BioPharma, Inc. has announced early indications of tumor stabilization in a patient enrolled in the Deltacel-01 Phase 1 clinical trial.
Read →
Nanobiotix Concludes Phase 1 Dose Escalation, Determines Phase 2 Dose for NBTXR3 in Re-Irradiation-Eligible Recurrent Lung Cancer
Pharma Pioneer
2 min read
Nanobiotix Concludes Phase 1 Dose Escalation, Determines Phase 2 Dose for NBTXR3 in Re-Irradiation-Eligible Recurrent Lung Cancer
17 May 2024
NANOBIOTIX has completed the dose escalation phase of a Phase 1 study evaluating NBTXR3, a potential first-in-class radioenhancer.
Read →
Corbus Commences U.S. Phase 1 Trial with First Patient Dosed for Next-Gen Nectin-4 ADC CRB-701
Pharma Pioneer
2 min read
Corbus Commences U.S. Phase 1 Trial with First Patient Dosed for Next-Gen Nectin-4 ADC CRB-701
17 May 2024
Corbus Pharmaceuticals, a precision oncology firm, has initiated a Phase 1 clinical trial in the U.S. for CRB-701 (SYS6002)
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.